They allow immunogenic components, including damage-associated molecular patterns (DAMPs), such as high mobility group proteins B1 (HMGB1) and inflammatory cytokines (i.e., interleukin [IL]-1β), to be released into the tumor microenvironment (10). The gene discussed is HMGB1; the disease is neoplasm.